VOICED : Bayer anuncia acuerdo de USD 10.000 millones con demandantes por herbicida en EEUU

Bayer has announced a significant settlement to compensate 125,000 claimants alleging cancer from Roundup, agreeing to pay over $10 billion. This settlement aims to resolve 75% of current litigation cases. However, Bayer will continue to appeal cases not included in this agreement. The company acquired Monsanto in 2019, inheriting these legal challenges. Bayer maintains that glifosato, the active ingredient in Roundup, is not harmful to human health, a stance it plans to defend in regulatory and scientific forums. Despite being classified as a probable carcinogen by the International Agency for Research on Cancer in 2015, Bayer denies any liability or wrongdoing.

What is the primary reason for Bayer's recent financial settlement?

• To invest in new technologies

• To settle a merger with Monsanto

• To compensate claimants alleging cancer from Roundup

• To expand their market share

How much is Bayer expected to pay in the settlement?

• Over $5 billion

• Over $10 billion

• Over $20 billion

• Over $15 billion

What is Bayer's position regarding the health effects of glyphosate?

• It is not harmful and unproven in court

• It has been proven harmful in court

• It is beneficial for health

• It is harmful to human health

What significant acquisition did Bayer make in 2019?

• Acquired Dow Chemical

• Acquired BASF

• Acquired Syngenta

• Acquired Monsanto

How did the International Agency for Research on Cancer classify Roundup in 2015?

• As a non-carcinogen

• As a safe herbicide

• As a definite carcinogen

• As a probable carcinogen